FDA approves SC Sarclisa (isatuximab-irfc) Escena + SOC for multiple myeloma patients across all existing indications of Sarclisa IV formulation July 15, 2026
FDA Approves REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA WT Locally Advanced or Metastatic Breast Cancer July 15, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Treatment Before and After Surgery for Adults With MIBC July 15, 2026
TEPKINLY (epcoritamab) in Combination with Lenalidomide & Rituximab Approved by the European Commission for the Treatment of R/R Follicular Lymphoma July 7, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as 1L Treatment of PD-L1+ (CPS ≥10) Advanced TNBC June 30, 2026
Enhertu approved in the EU for patients with previously treated HER2+ve metastatic solid tumours June 30, 2026
NMPA approves satricabtagene autoleucel for treating 3L+ Claudin18.2+ve, HER2-neg advanced G/GEJA June 30, 2026
FDA Approves IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance June 30, 2026
Japan Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of R/R DLBCL Announced June 23, 2026
Sarclisa SQ approved in the EU as the first anticancer treatment administered via an on-body injector June 17, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant Treatment of Certain Patients With Clear Cell RCC June 17, 2026
China NMPA Approves TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer June 17, 2026
Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy June 17, 2026
European Commission Authorizes Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in 1L CLL June 2, 2026
DARZALEX® (daratumumab) injectable approved for administration by patients or caregivers for treatment of multiple myeloma June 2, 2026
Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma June 2, 2026
Datroway approved in the US in 1L metastatic TNBC patients not PD-1/PD-L1 inhibitor candidates May 26, 2026
US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo May 21, 2026
Enhertu approved for use before surgery based on DESTINY-Breast11 Ph 3 trial and following surgery based on DESTINY-Breast05 Ph 3 trial in HER2-positive early breast cancer May 21, 2026
